Oregon Public Employees Retirement Fund decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 389,445 shares of the biopharmaceutical company’s stock after selling 202,282 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Gilead Sciences were worth $22,689,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in the business. TFO TDC LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $26,000. Tortoise Investment Management LLC lifted its holdings in shares of Gilead Sciences by 81.6% during the fourth quarter. Tortoise Investment Management LLC now owns 445 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 200 shares in the last quarter. Graves Light Private Wealth Management Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $27,000. Advisory Alpha LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth $28,000. Finally, Joseph P. Lucia & Associates LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. 76.36% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:GILD traded down $0.82 during midday trading on Tuesday, hitting $63.29. 300,542 shares of the stock were exchanged, compared to its average volume of 8,977,984. The stock has a market capitalization of $79.34 billion, a price-to-earnings ratio of 66.09, a P/E/G ratio of 0.67 and a beta of 0.51. The company has a debt-to-equity ratio of 1.65, a quick ratio of 3.15 and a current ratio of 3.25. The business’s 50-day moving average price is $65.08 and its 200 day moving average price is $63.01. Gilead Sciences, Inc. has a 12 month low of $56.56 and a 12 month high of $85.97.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, February 4th. The biopharmaceutical company reported $2.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.15 by $0.04. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.06 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 30th. Stockholders of record on Monday, March 15th will be issued a dividend of $0.71 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.68. This represents a $2.84 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend is Friday, March 12th. Gilead Sciences’s payout ratio is 44.30%.
A number of equities research analysts have recently weighed in on the company. UBS Group assumed coverage on Gilead Sciences in a report on Wednesday, October 28th. They set a “neutral” rating and a $61.00 target price for the company. Redburn Partners began coverage on Gilead Sciences in a research note on Monday, December 14th. They issued a “neutral” rating for the company. Morgan Stanley boosted their price target on Gilead Sciences from $83.00 to $87.00 and gave the company an “overweight” rating in a research note on Friday, February 5th. Barclays dropped their price target on Gilead Sciences from $67.00 to $62.00 in a research note on Thursday, October 29th. Finally, Smith Barney Citigroup dropped their price target on Gilead Sciences from $75.00 to $72.00 in a research note on Tuesday, December 22nd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the company. Gilead Sciences currently has an average rating of “Hold” and an average target price of $94.93.
In related news, EVP Brett A. Pletcher sold 1,975 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total value of $133,134.75. Following the transaction, the executive vice president now directly owns 28,832 shares of the company’s stock, valued at $1,943,565.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: What is the CAC 40 Index?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.